医学
数据库
梅德林
环境卫生
计算机科学
法学
政治学
作者
Jiangfeng Wang,Xiaochun Zheng,Jingyang Lin,Jinlong Huang,Miaomiao Zhang,Ping Huang,Xiuli Yang
出处
期刊：BMJ Open
[BMJ]
日期：2024-10-01
卷期号：14 (10): e084991-e084991
标识
DOI：10.1136/bmjopen-2024-084991
摘要
Zanubrutinib is a second-generation Bruton's tyrosine kinase inhibitor that has been approved for the treatment of several B cell malignancies. The aim of this study was to evaluate adverse events (AEs) associated with zanubrutinib based on the real-world data.
科研通智能强力驱动
Strongly Powered by AbleSci AI
爱静静
丰盛的煎饼
西红柿炒番茄
乐乐乐乐乐乐
加菲丰丰
Hayat
寻道图强
kento
ShowMaker
杳鸢
YifanWang
贰鸟
冒险寻羊
spark810
lanxinyue
景辣条
大仙
互助遵法尚德
yyymmma
斯文败类
皖公网安备34019202002308
